Medical Devices

With CE Mark approval, Countable Labs brings single-molecule counting PCR to Europe, promising unprecedented precision for gene therapy and diagnostics.

Health Canada greenlights MeMed's rapid diagnostic tool, a major step in the nation's fight against deadly sepsis and growing antimicrobial resistance.

With $138M in total funding, Endogenex is advancing a novel device that aims to redefine type 2 diabetes treatment by healing the gut, not just managing symptoms.

Biolojic Design's adaptive AI drug for asthma and eczema hits a key milestone with Teva, heralding a new era for personalized autoimmune treatment.

From the heart of Arabia, AlUla Peregrina brings a patented active to the global stage, promising scientifically-backed, ethical longevity beauty.

As funding expires for Wayne State's 35-year heart experiments on dogs, advocates and lawmakers urge the NIH to end a legacy of waste and suffering.

A 50% surge in surrogate insurance demand signals India's new regulated era, but experts warn that inadequate coverage leaves surrogate mothers at grave risk.

Venture capital leaders and national security experts caution that drug pricing controls and regulatory hurdles could cede America's biomedical edge to rivals.

Pixee Medical's AR glasses are challenging costly robots, offering surgeons a new, highly accurate, and efficient way to perform knee replacements.

A new AI-driven, non-invasive test could solve the diagnostic puzzle of INOCA, a heart condition that disproportionately affects millions of women.

Venture firm Sonder Capital closes its new fund with backing from Mayo Clinic and Sutter Health, aiming to revolutionize patient care with AI-powered robotics.

Biotronik launches a global study for its LivIQ system, a single-device leadless pacemaker using novel far-field sensing to restore a natural heartbeat.

With a top expert at the helm, AltaThera aims to expand its heart rhythm drug for kids, balancing life-saving potential with critical safety warnings.

A breakthrough in mycelium-based infection detection has prompted Mushrooms Inc. to halt a merger, betting its future on its own innovative biotech platform.

As demand for non-opioid solutions soars, OrthoLazer expands its high-tech, standardized laser therapy, aiming to redefine orthopedic wellness nationally.

Xtressé's Xvie, an injectable therapy using extracellular vesicles, has been cleared for human trials, offering new hope for androgenetic alopecia.

The expanded partnership aims to standardize care and meet soaring demand in Northwest Arkansas, integrating two new surgical facilities into the system.

LiviWell's Livi device, the first of its kind, gets FDA clearance to absorb post-sex fluids, aiming to improve comfort and vaginal health.

With 35+ years of orthopedic sales experience, Thurman Ballard joins Tetrous to drive adoption of its groundbreaking bone-to-tendon healing technology.

With new financing from Avenue Capital, Turn Therapeutics bets big on its novel skin therapy, GX-03, to tackle multi-billion dollar dermatology markets.